Climb Bio (CLYM) Notes Payables (2020 - 2022)

Climb Bio's (CLYM) quarterly Notes Payables came in at $21000.0 in Q2 2022, down 89.86% on a QoQ basis from $207000.0 in Q4 2020.

Climb Bio (CLYM) Notes Payables (2020 - 2022) Analysis & Trends

Climb Bio (CLYM) has 2 years of Notes Payables data on file, last reported at $21000.0 in Q2 2022.

Quarterly Notes Payables changed N/A year-over-year to $21000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $21000.0 (changed N/A YoY) and the FY2020 annual result came in at $207000.0, changed N/A from the prior year.
Notes Payables fell to $21000.0 in Q2 2022, from $207000.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $207000.0 in Q4 2020 to a low of $21000.0 in Q2 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Climb Bio	1.24 Bn	1.24 Bn	-

Historic Data

Download Data

Date	Value
Jun 30, 2022	21,000.00
Dec 31, 2020	207,000.00